The Alzheimer's Association is working hard to ensure a smooth rollout for patients who can benefit from lecanemab

Yesterday, the FDA granted traditional approval to lecanemab (sold under the brand name Leqembi), the first Alzheimer's treatment that changes the underlying course of the disease. This is a momentous occasion for the Alzheimer's community, and many congratulations to Eisai and Biogen!

Lecanemab is a monoclonal antibody that targets amyloid plaques, which are a hallmark of Alzheimer's disease. In clinical trials, lecanemab was shown to slow the decline of cognitive function and daily activities in people with early-stage Alzheimer's disease.?

The approval of lecanemab is a significant step forward in the fight against Alzheimer's disease. However, it is important to remember that lecanemab is not a cure. It is a treatment that can help to slow the progression of the disease, but it does not stop it.?

The next step is to ensure that CMS, payers, and the HCP community can work together to make lecanemab available to patients who can benefit from it. HealthLink Dimensions is proud to support our long-time partners at the Alzheimer's Association as they work with these stakeholders to ensure that patients have access to this important treatment.?

If you or someone you know has been diagnosed with Alzheimer's disease, please talk to your doctor about whether lecanemab may be right for you.?

?